| Literature DB >> 30871616 |
Hamed Tahmasebi1, Sanaz Dehbashi2, Mohammad Reza Arabestani3,4.
Abstract
OBJECTIVE: Methicillin-resistant Staphylococcus aureus cause to a variety of hard to cure infections. MRSA isolates also, produce an arsenal of virulence factors contribute to severe infections. The aim of this study was to find out the relationship between agr locus and presence of S. aureus superantigens (SAgs).Entities:
Keywords: Methicillin-resistant Staphylococcus aureus; Superantigens; Virulence factors; agr locus
Mesh:
Substances:
Year: 2019 PMID: 30871616 PMCID: PMC6419358 DOI: 10.1186/s13104-019-4166-7
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Fig. 1Distribution of different samples between Group 1 and Group 2 Staphylococcus aureus
Antimicrobial resistance profiles of MRSA, MSSA, and S. aureus isolates
| Antibiotics | Group1 | Group2 |
| |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRSAa | MSSAb | MRSA | MSSA | Group 1 | Group 2 | |||||||||||||
| Rc | Id | Se | R | I | S | R | I | S | R | I | S | R | I | S | R | I | S | |
| Penicillin | 61 | 0 | 0 | 68 | 0 | 31 | 99 | 0 | 0 | 70 | 0 | 21 | 129 | 0 | 31 | 169 | 0 | 21 |
| Tetracycline | 58 | 2 | 1 | 21 | 9 | 69 | 64 | 2 | 33 | 40 | 9 | 42 | 79 | 11 | 70 | 104 | 11 | 75 |
| Clindamycin | 49 | 4 | 8 | 35 | 9 | 55 | 69 | 4 | 26 | 28 | 2 | 61 | 84 | 13 | 63 | 97 | 6 | 87 |
| Gentamicin | 59 | 0 | 2 | 32 | 8 | 59 | 79 | 11 | 9 | 9 | 8 | 74 | 91 | 8 | 61 | 88 | 19 | 83 |
| Ciprofloxacin | 55 | 5 | 1 | 33 | 12 | 54 | 94 | 2 | 3 | 27 | 1 | 63 | 88 | 17 | 55 | 121 | 3 | 66 |
| Erythromycin | 47 | 3 | 11 | 22 | 9 | 71 | 58 | 6 | 35 | 50 | 0 | 41 | 50 | 9 | 82 | 108 | 6 | 76 |
| Chloramphenicol | 57 | 0 | 4 | 40 | 11 | 48 | 83 | 7 | 9 | 15 | 4 | 72 | 97 | 11 | 52 | 98 | 11 | 81 |
| Linezolid | 4 | 0 | 57 | 0 | 0 | 99 | 6 | 0 | 93 | 1 | 0 | 90 | 4 | 0 | 156 | 7 | 0 | 183 |
| Trimethoprim/sulfamethoxazole | 27 | 3 | 31 | 22 | 1 | 76 | 37 | 6 | 56 | 14 | 3 | 74 | 49 | 4 | 107 | 51 | 9 | 130 |
| Rifampicin | 7 | 0 | 54 | 4 | 0 | 95 | 8 | 0 | 91 | 1 | 0 | 90 | 11 | 0 | 149 | 9 | 0 | 181 |
| MIC (µg/ml) | ||||||||||||||||||
| Vancomycin | 0 | 2 | 59 | 0 | 0 | 99 | 0 | 4 | 95 | 0 | 0 | 91 | 0 | 2 | 158 | 0 | 4 | 186 |
| Oxacillin | 59 | 2 | 0 | 0 | 0 | 99 | 98 | 1 | 0 | 0 | 0 | 91 | 59 | 9 | 92 | 98 | 4 | 88 |
| Cefoxitin | 61 | 0 | 0 | 0 | 0 | 99 | 99 | 0 | 0 | 0 | 0 | 91 | 61 | 11 | 88 | 99 | 5 | 86 |
Prevalence of SAgs genes in S. aureus isolates from patients of Group 1 and Group 2
| SAgs and toxins | Group 1 | Group 2 | MRSA | MSSA | Total in Group 1 | Total in Group 2 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Female | Male | Female | Male | Group 1 | Group 2 | Group 1 | Group 2 | |||
|
| 5 | 12 | 11 | 14 | 11 | 20 | 6 | 6 | 17 | 26 |
|
| 1 | 10 | 9 | 10 | 7 | 11 | 4 | 8 | 11 | 19 |
|
| 3 | 2 | 5 | 16 | 6 | 19 | 0 | 2 | 5 | 21 |
|
| 11 | 2 | 1 | 16 | 9 | 13 | 4 | 7 | 13 | 17 |
|
| 4 | 11 | 6 | 13 | 6 | 16 | 9 | 3 | 15 | 19 |
| 0 | 2 | 8 | 8 | 2 | 11 | 0 | 5 | 2 | 16 | |
| 1 | 5 | 3 | 13 | 5 | 9 | 1 | 7 | 6 | 16 | |
|
| 4 | 3 | 7 | 13 | 6 | 15 | 1 | 5 | 7 | 20 |
| 5 | 6 | 2 | 9 | 7 | 16 | 4 | 2 | 11 | 14 | |
| 1 | 6 | 1 | 6 | 6 | 11 | 1 | 2 | 7 | 13 | |
| 4 | 5 | 2 | 7 | 4 | 19 | 5 | 2 | 9 | 21 | |
| 2 | 9 | 5 | 6 | 10 | 17 | 1 | 9 | 11 | 26 | |
| 5 | 7 | 5 | 7 | 9 | 11 | 3 | 8 | 12 | 19 | |
| 9 | 13 | 7 | 15 | 16 | 23 | 6 | 6 | 22 | 29 | |
| 8 | 13 | 9 | 12 | 19 | 17 | 2 | 2 | 21 | 19 | |
| 0 | 1 | 4 | 10 | 1 | 9 | 0 | 5 | 1 | 14 | |
|
| 0 | 0 | 3 | 8 | 0 | 9 | 0 | 3 | 0 | 11 |
|
| 0 | 0 | 3 | 6 | 0 | 8 | 0 | 1 | 0 | 9 |
| 0 | 2 | 2 | 4 | 2 | 5 | 0 | 3 | 2 | 8 | |
| 0 | 0 | 3 | 8 | 0 | 5 | 0 | 6 | 0 | 11 | |
| 0 | 0 | 2 | 4 | 0 | 6 | 0 | 0 | 0 | 6 | |
|
| 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
|
| 49 | 12 | 67 | 32 | 61 | 99 | 0 | 0 | 61 | 99 |